SK312004A3 - Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions - Google Patents

Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions Download PDF

Info

Publication number: SK312004A3
Authority: SK; Slovakia
Prior art keywords: treatment; disease; pharmaceutically acceptable; diseases; acid addition
Prior art date: 2001-07-18

Application number

SK31-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Istvan Gacsalyi

Gyorgy Levay

Gyonos Ildiko Nagyne

Laszlo Gabor Harsing

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-18

Filing date

2002-07-18

Publication date

2004-06-08

2002-07-18 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2004-06-08 Publication of SK312004A3 publication Critical patent/SK312004A3/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 29
230000003920 cognitive function Effects 0.000 title claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 title claims description 19
230000007423 decrease Effects 0.000 title abstract 2
229950011405 deramciclane Drugs 0.000 title description 11
QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 title description 11
150000001875 compounds Chemical class 0.000 claims abstract description 29
201000010099 disease Diseases 0.000 claims abstract description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
230000003340 mental effect Effects 0.000 claims abstract description 22
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims abstract description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 16
230000006735 deficit Effects 0.000 claims description 16
125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims description 14
208000024827 Alzheimer disease Diseases 0.000 claims description 12
230000006806 disease prevention Effects 0.000 claims description 11
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
208000023105 Huntington disease Diseases 0.000 claims description 7
208000006264 Korsakoff syndrome Diseases 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
230000009467 reduction Effects 0.000 claims description 7
208000018737 Parkinson disease Diseases 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
206010039966 Senile dementia Diseases 0.000 claims description 5
206010012289 Dementia Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
JSZIERUELMKQRO-WLHGVMLRSA-N (e)-but-2-enedioic acid;heptane Chemical compound CCCCCCC.OC(=O)\C=C\C(O)=O JSZIERUELMKQRO-WLHGVMLRSA-N 0.000 claims description 2
239000012752 auxiliary agent Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
238000012545 processing Methods 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
208000015114 central nervous system disease Diseases 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 28
238000012360 testing method Methods 0.000 description 10
230000035939 shock Effects 0.000 description 8
230000014759 maintenance of location Effects 0.000 description 7
230000015654 memory Effects 0.000 description 7
230000007704 transition Effects 0.000 description 7
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
230000000949 anxiolytic effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000007787 long-term memory Effects 0.000 description 5
230000006870 function Effects 0.000 description 4
208000028698 Cognitive impairment Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
208000010877 cognitive disease Diseases 0.000 description 3
ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical class C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000006403 short-term memory Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
-1 hydrogen halides Chemical class 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000006386 memory function Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000003997 social interaction Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010027374 Mental impairment Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009933 burial Methods 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
229960002456 hexobarbital Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000005056 memory consolidation Effects 0.000 description 1
230000007074 memory dysfunction Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK31-2004A 2001-07-18 2002-07-18 Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions SK312004A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0103017A HUP0103017A3 (en)	2001-07-18	2001-07-18	Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use
PCT/HU2002/000069 WO2003007926A2 (en)	2001-07-18	2002-07-18	Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions

Publications (1)

Publication Number	Publication Date
SK312004A3 true SK312004A3 (en)	2004-06-08

Family

ID=90001562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK31-2004A SK312004A3 (en)	2001-07-18	2002-07-18	Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions

Country Status (18)

Country	Link
US (1)	US20040171696A1 (cs)
EP (1)	EP1408940B1 (cs)
JP (1)	JP2004537548A (cs)
KR (1)	KR20040017326A (cs)
CN (1)	CN1545410A (cs)
AT (1)	ATE408403T1 (cs)
CA (1)	CA2453834A1 (cs)
CZ (1)	CZ200460A3 (cs)
DE (1)	DE60228968D1 (cs)
EA (1)	EA006897B1 (cs)
HU (1)	HUP0103017A3 (cs)
IL (1)	IL159841A0 (cs)
PL (1)	PL365258A1 (cs)
RS (1)	RS4904A (cs)
SK (1)	SK312004A3 (cs)
UA (1)	UA78714C2 (cs)
WO (1)	WO2003007926A2 (cs)
ZA (1)	ZA200400481B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0301537A3 (en) *	2003-06-03	2005-07-28	Egis Gyogyszergyar Nyilvanosan	Deramcyclane fumarate tablets and process for producing them
HUP0301906A3 (en) *	2003-06-23	2006-03-28	Egis Gyogyszergyar Nyilvanosan	Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity
EP1500391A1 (en) *	2003-07-24	2005-01-26	Neuro3D	Therapeutic use of bicycloheptane derivatives
WO2005087212A1 (en) *	2004-03-12	2005-09-22	Egis Gyógyszergyár Nyrt.	Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
RS20060504A (sr) *	2004-03-12	2008-09-29	Egis Gyogyszergyar Nyrt.,	Kombinacija deramciklana i opioda kao analgetika
KR101642113B1 (ko)	2014-10-08	2016-07-25	원광대학교산학협력단	퇴행성 뇌질환을 예방, 개선 또는 치료하는 유황의 법제 방법 및 상기 방법으로 법제된 유황
US11478467B2 (en)	2017-05-04	2022-10-25	Sreenivasarao Vepachedu	Targeted drug rescue with novel compositions, combinations, and methods thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU179164B (en) *	1979-12-14	1982-08-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing cycloalkyl-ethers of alkanolamines
HU226061B1 (en) *	1996-10-17	2008-04-28	Egis Gyogyszergyar Nyilvanosan	1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
HU227114B1 (en) *	1999-05-11	2010-07-28	Egis Gyogyszergyar Nyilvanosan	(1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
US6335371B1 (en) *	2000-11-28	2002-01-01	Orion Corporation	Method for inducing cognition enhancement

2001
- 2001-07-18 HU HU0103017A patent/HUP0103017A3/hu unknown
2002
- 2002-07-18 SK SK31-2004A patent/SK312004A3/sk not_active Application Discontinuation
- 2002-07-18 IL IL15984102A patent/IL159841A0/xx unknown
- 2002-07-18 UA UA2004021167A patent/UA78714C2/uk unknown
- 2002-07-18 PL PL02365258A patent/PL365258A1/xx not_active Application Discontinuation
- 2002-07-18 JP JP2003513535A patent/JP2004537548A/ja active Pending
- 2002-07-18 EP EP02745700A patent/EP1408940B1/en not_active Expired - Lifetime
- 2002-07-18 CN CNA028163729A patent/CN1545410A/zh active Pending
- 2002-07-18 KR KR10-2004-7000792A patent/KR20040017326A/ko not_active Abandoned
- 2002-07-18 WO PCT/HU2002/000069 patent/WO2003007926A2/en not_active Ceased
- 2002-07-18 RS YU4904A patent/RS4904A/sr unknown
- 2002-07-18 AT AT02745700T patent/ATE408403T1/de not_active IP Right Cessation
- 2002-07-18 EA EA200400192A patent/EA006897B1/ru not_active IP Right Cessation
- 2002-07-18 CA CA002453834A patent/CA2453834A1/en not_active Abandoned
- 2002-07-18 CZ CZ200460A patent/CZ200460A3/cs unknown
- 2002-07-18 DE DE60228968T patent/DE60228968D1/de not_active Expired - Fee Related
- 2002-07-18 US US10/483,808 patent/US20040171696A1/en not_active Abandoned
2004
- 2004-01-22 ZA ZA200400481A patent/ZA200400481B/en unknown

Also Published As

Publication number	Publication date
IL159841A0 (en)	2004-06-20
WO2003007926A3 (en)	2003-09-18
EP1408940A2 (en)	2004-04-21
CN1545410A (zh)	2004-11-10
US20040171696A1 (en)	2004-09-02
ATE408403T1 (de)	2008-10-15
WO2003007926A2 (en)	2003-01-30
CZ200460A3 (cs)	2004-05-12
UA78714C2 (en)	2007-04-25
EA200400192A1 (ru)	2004-06-24
JP2004537548A (ja)	2004-12-16
RS4904A (sr)	2006-10-27
DE60228968D1 (de)	2008-10-30
EA006897B1 (ru)	2006-04-28
HUP0103017D0 (en)	2001-10-28
HUP0103017A3 (en)	2004-05-28
HUP0103017A2 (hu)	2003-07-28
EP1408940B1 (en)	2008-09-17
ZA200400481B (en)	2005-01-24
CA2453834A1 (en)	2003-01-30
KR20040017326A (ko)	2004-02-26
PL365258A1 (en)	2004-12-27

Legal Events

Date	Code	Title	Description
2011-08-04	FC9A	Refused patent application

Publication	Publication Date	Title
HU202108B (en)	1991-02-28	Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
KR20140038378A (ko)	2014-03-28	바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
US6417206B1 (en)	2002-07-09	Antitussive/antihist aminic/decongestant compositions
AU608922B2 (en)	1991-04-18	Method for the treatment of anxiety
CZ200460A3 (cs)	2004-05-12	Název neuveden
AU2012258339A1 (en)	2013-06-27	New combination between 4-{3-[Cis-Hexahydrocyclopenta[c]Pyrrol-2(1H)-yl]Propoxy}Benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it
AU2020271363A1 (en)	2021-11-18	Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
ITMI951417A1 (it)	1997-01-03	Composizioni farmaceutiche e procedimento per la loro preparazione
SK50082006A3 (sk)	2006-05-04	Použitie bicyklo[2.2.1]heptánových derivátov na prípravu neuroprotektívnych farmaceutických kompozícií
US6962921B2 (en)	2005-11-08	Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
CZ20023025A3 (cs)	2003-05-14	Léčba chorob vztahujících se k serotonergnímu systému
CA3162938C (en)	2025-12-02	Methods for treating behavioral and psychological symptoms in patients with dementia
EP4069231B1 (en)	2025-07-09	Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia
SK17142000A3 (sk)	2001-06-11	Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety
AU2002317412A1 (en)	2003-03-03	Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions
HK1069113A (en)	2005-05-13	Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
EP0621781A1 (en)	1994-11-02	Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses
HK40071167B (zh)	2024-10-25	用於在患有痴呆的患者中治疗行为和心理症状的方法
CZ284061B6 (cs)	1998-08-12	Použití isethionátu 3,5-diamino-6-(2,3-dichlorfenyl)-1,2,4-triazinu pro výrobu léčiva pro ošetřování a prevenci závislosti, tolerance a citlivosti k drogám
HK40071167A (en)	2022-11-04	Methods for treating behavioral and psychological symptoms in patients with dementia
EA047219B1 (ru)	2024-06-21	Способы лечения поведенческих и психологических симптомов у пациентов с деменцией